About chemomab therapeutics - CMMB
Chemomab Therapeutics Ltd. is a clinical-stage biotech company, which engages in the provision of therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.
CMMB At a Glance
Chemomab Therapeutics Ltd.
Kiryat Atidim
Tel Aviv, Tel Aviv 6158002
| Phone | 972-77-331-0156 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -9,066,357.18 | |
| Sector | Health Technology | Employees | 12 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CMMB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.962 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.016 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
CMMB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -755,529.765 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CMMB Liquidity
| Current Ratio | 9.083 |
| Quick Ratio | 9.083 |
| Cash Ratio | 7.014 |
CMMB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -58.919 |
| Return on Equity | -70.089 |
| Return on Total Capital | -73.508 |
| Return on Invested Capital | -69.528 |
CMMB Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |